Acrivon Therapeutics, Inc.
Acrivon Therapeutics, Inc. (ACRV): 3 pipeline candidates · ~14 mo cash runway · 2 clinical trials. Updated within the last hour.
BioSniper Score
5-factor signal · derived from public data
13.9 months
D/E 0.13 · 0% dilution
Lead: Phase 2
3 candidates
N/A
3 buys · 0 sells (180d)
A transparent, data-derived signal for Acrivon Therapeutics, Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$65.1M
Cash
$34.3M
Quarterly Burn
$20.5M
Runway
13.9 mo
Revenue
—
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (3 candidates)
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
43
Total value held
$19.2M
| Holder | Shares | Value |
|---|---|---|
| ra capital management, l.p. | 8,340,508 | $11.6M |
| vanguard capital management llc | 1,444,070 | $2.0M |
| wellington management group llp | 888,130 | $1.2M |
| renaissance technologies llc | 758,440 | $1.1M |
| marshall wace, llp | 560,436 | $779K |
| two sigma investments, lp | 389,395 | $541K |
| jane street group, llc | 239,691 | $333K |
| geode capital management, llc | 236,391 | $329K |
| blackrock, inc. | 208,939 | $290K |
| bridgeway capital management, llc | 158,900 | $221K |
Showing top 10 of 43 institutional holders of Acrivon Therapeutics, Inc.. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in Acrivon Therapeutics, Inc.'s pipeline?
Acrivon Therapeutics, Inc. (ACRV) has 3 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Acrivon Therapeutics, Inc.'s lead drug candidate?
Acrivon Therapeutics, Inc.'s most advanced tracked candidate is ACR-2316 (Phase 1) for Specific Advanced Solid Tumors.
What is Acrivon Therapeutics, Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Acrivon Therapeutics, Inc. has approximately 13.9 months of cash runway.
What is Acrivon Therapeutics, Inc.'s market capitalization?
Acrivon Therapeutics, Inc.'s market capitalization is approximately $65.1M.
Who is the CEO of Acrivon Therapeutics, Inc.?
Dr. Peter Blume-Jensen M.D., Ph.D. is the chief executive officer of Acrivon Therapeutics, Inc. (ACRV).
Get the full picture on Acrivon Therapeutics, Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.